CJJK(SZ:002435)2023-04-19 16:00Financial Performance - The company's operating revenue for 2022 was ¥3,469,557,831.87, a decrease of 20.60% compared to ¥4,369,815,125.02 in 2021[6]. - The net profit attributable to shareholders for 2022 was ¥65,190,392.13, representing a significant increase of 115.79% from a loss of ¥412,986,660.97 in 2021[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,660,068.45, up 103.79% from a loss of ¥597,984,717.38 in 2021[6]. - The net cash flow from operating activities increased by 77.72% to ¥523,058,080.76 from ¥294,312,912.85 in 2021[6]. - The total assets at the end of 2022 were ¥7,371,749,936.56, an increase of 2.82% from ¥7,169,632,208.56 at the end of 2021[6]. - The basic earnings per share for 2022 was ¥0.0527, a recovery from a loss of ¥0.3341 in 2021, marking an increase of 115.77%[6]. - The company reported a weighted average return on equity of 1.44% for 2022, a significant improvement from -8.72% in 2021[6]. - The company received government subsidies amounting to ¥23,622,681.24 in 2022, down from ¥37,461,590.11 in 2021[6]. - The company achieved total operating revenue of CNY 3,469,557,831.8, a year-on-year decrease of 20.60%[45]. - The net profit attributable to shareholders was CNY 65,190,400, an increase of 115.79% compared to the previous year[45]. Business Operations - The company has not made significant changes to its main business, which focuses on pharmaceutical product research, production, and sales, as well as specialized medical services in obstetrics and gynecology[22]. - The company completed the acquisition of 100% equity in Changjiang Runfa Zhangjiagang Free Trade Zone Pharmaceutical Investment Co., Ltd. in 2016, adding pharmaceutical assets to its portfolio[21]. - The company operates in the pharmaceutical industry, focusing on research, production, and sales, with significant contributions from its subsidiaries, including Hailing Pharmaceutical and Huaxin Pharmaceutical[38]. - Hailing Pharmaceutical has over 130 product specifications and ranks second in the domestic public hospital market for systemic antibacterial drugs, with core products like "Injectable Cefotaxime" and "Injectable Cefoperazone" ranking fourth and fifth respectively[39]. - The company has achieved consistency evaluation for 12 products and 23 specifications in the past three years, with 5 products and 9 specifications successfully winning bids in centralized procurement[39]. - The company is expanding its women's and children's healthcare services in response to the increasing demand driven by the "three-child" policy and rising rates of gynecological diseases among women[36]. - The company has expanded its hospital coverage to over 3,000 hospitals, achieving a hospital coverage rate of 39.83%[45]. - The company is committed to innovation, with ongoing research and development efforts to enhance its product line and improve quality control systems[41]. Market and Sales - The pharmaceutical segment generated revenue of CNY 1,649,420,555.3, accounting for 47.54% of total revenue, with a year-on-year decline of 27.29%[48]. - The elevator guide rail segment reported revenue of CNY 1,820,137,276.5, representing 52.46% of total revenue, down 13.38% year-on-year[48]. - The company achieved a 101.62% increase in the equity acquisition project of Shandong Huaxin, with a total investment of RMB 28,477 million[77]. - The company plans to enhance its product pipeline through the approval of generic drugs and improved formulations, aiming for a significant market impact[60]. - The company is exploring strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of 2023[112]. Research and Development - The company is investing 200 million RMB in R&D for new technologies in the healthcare sector over the next two years[112]. - Research and development expenses increased by 25% in 2022, totaling 5,500 million, to support innovation[191]. - The company plans to obtain production approval for 5 new products and initiate 24 new projects in 2023, with a focus on accelerating 33 ongoing products[87]. - The company is conducting clinical trials for new functions of its proprietary product, with exclusivity protection extending until 2030[60]. Environmental Compliance - The company strictly adheres to environmental protection laws and regulations, with no penalties incurred for violations during the reporting period[144]. - The company has implemented new technologies in wastewater treatment, enhancing overall efficiency and compliance[147]. - The company is focused on maintaining compliance with water pollution discharge standards across its facilities[149]. - The company emphasizes energy structure optimization and clean production, aligning with national goals of carbon peak and carbon neutrality[154]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[3]. - The company has established an independent financial department with a complete accounting system, allowing for independent financial decision-making and self-accounting[101]. - The company maintains clear ownership of assets, with no instances of funds or resources being occupied or used by the controlling shareholder[101]. - The company has a complete production and administrative organization that operates independently from the controlling shareholder, with no interference from any external parties[101]. Employee and Management - The total number of employees at the end of the reporting period was 2,405, with 2,384 from major subsidiaries[130]. - The company has a competitive salary system based on internal and external labor market conditions, with a clear structure including basic salary, performance pay, and various allowances[131]. - The company’s training plan includes various categories such as pre-job training, industry knowledge, and management training to enhance employee skills[132]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 653.37 million CNY[119]. Future Outlook - The company has set a revenue guidance of 1.5 billion RMB for the fiscal year 2023, projecting a growth of 25% compared to 2022[112]. - The company plans to use retained earnings primarily for operational funding, external investments, acquisitions, and major capital expenditures to promote business growth[135]. - The company aims to reduce operational costs by 15% through efficiency improvements and automation initiatives[112]. - The company has set a performance guidance for 2023, targeting a revenue growth of 30%[191].